Anil Kumar Sood

8299040, Oct 30, 2012

Oct 5, 2007

11/867717

Kapil Mehta - Bellaire TX, US
Amit Verma - Haryana, IN
Sushovan Guha - Missouri City TX, US
Jansina Fok - Houston TX, US
Anil Sood - Pearland TX, US

Board of Regents, The University of Texas System - Austin TX

C07H 21/02
C07H 21/04
A61K 31/70
C12Q 1/68

514 44A, 536 231, 536 241, 536 245, 435375, 435377

A method for treating cancer comprising inhibiting transglutaminase activity is provided. Suitable cancer types for which the methods of the present disclosure can be used to treat include, but are not limited to, pancreatic, breast, and ovarian cancers and melanoma. The inhibition of transglutaminase activity may be performed by one or more techniques, including, but not limited to, downregulating transglutaminase expression, inhibiting TG2 translation, or blocking TG2 enzymatic activity, such as with a small molecule inhibitor or intracellular antibody (intrabody).

8440393, May 14, 2013

Aug 14, 2009

12/541729

Michael J. Birrer - Mt. Airy MD, US
Tomas A. Bonome - Washington DC, US
Anil Sood - Pearland TX, US
Chunhua Lu - Missouri City TX, US

The United States of America as Represented by the Secretary of the Department of Health and Human Services - Washington DC
The University of MD Anderson Cancer Center - Houston TX

C12Q 1/00
C12Q 1/68
G01N 33/53
G01N 33/567
G01N 33/574
C12N 15/11

435 4, 435 61, 435 614, 435 71, 435 721, 435 723, 514 44 A

A gene profiling signature for ovarian tumor endothelial cells is disclosed herein. The gene signature can be used to diagnosis or prognosis an ovarian tumor, identify agents to treat an ovarian tumor, to predict the metastatic potential of an ovarian tumor and to determine the effectiveness of ovarian tumor treatments. Thus, methods are provided for identifying agents that can be used to treat ovarian cancer, for determining the effectiveness of an ovarian tumor treatment, or to diagnose or prognose an ovarian tumor. Methods of treatment are also disclosed which include administering a composition that includes a specific binding agent that specifically binds to one of the disclosed ovarian endothelial cell tumor-associated molecules and inhibits ovarian tumor in the subject.

8466154, Jun 18, 2013

Oct 29, 2007

11/927329

Ariel Fernandez - Houston TX, US
William Bornmann - Missouri City TX, US
Angela Sanguino - Pittsburgh PA, US
Zheng-Hong Peng - Missouri City TX, US
Anil K. Sood - Pearland TX, US

The Board of Regents of the University of Texas System - Austin TX

A61K 31/496
C07D 403/14

51425211, 544295

This application describes a novel technology in drug discovery and drug-based imaging/detection: the wrapping technology. This technology is based on identified singularities in the structure of soluble proteins. In contrast with drug-design approaches based on standard structural considerations, the packing of a protein, or more precisely, its dehydron pattern, may be used as a selectivity filter to design small-molecule inhibitors. The wrapping technology described herein is a novel form of rational drug design for avoiding side effects in drug therapy and sharpening the inhibitory impact of drugs on the oncokinome.

20090012021, Jan 8, 2009

Apr 17, 2006

11/911639

Anil K. Sood - Pearland TX, US
Charles N. Landen - Pearland TX, US
Arturo Chavez-Reyes - Monterey, MX

A61K 31/7052
C12N 5/00
A61K 48/00
A61P 35/00

514 44, 435325

The present invention relates to the fields of molecular biology and drug delivery. In certain embodiments, the present invention provides methods for the delivery of a siNA (e.g., a siRNA) to a cell via a neutral (non-charged) liposome. These methods may be used to treat a disease, such as cancer.

20090306186, Dec 10, 2009

May 28, 2009

12/474017

David B. JACKSON - Heidelberg, DE
Martin Stein - Mannheim, DE
Hartmut Voss - Schriesheim, DE
Stephan Brock - Weinheim, DE
Christopher G. Danes - Delmar NY, US
Anil Sood - Pearland TX, US

A61K 31/7088
C12Q 1/68
A61P 7/00

514 44 A, 435 6

There is disclosed a molecular composition(s) of a novel tissue protective erythropoietin (EPO) binding receptor protein complex, termed NEPOR. Presence of NEPOR components on a tumour allows EPO to impinge on the survival of associated cells thereby enhancing tumour progression and negatively effecting patient survival. Presence of NEPOR represents a prognostic biomarker for poorer patient outcome. Thus, methods are provided for stratifying patients having a tumour as suitable (i.e. NEPOR not present) or non-suitable (i.e., NEPOR present) for EPO treatment, comprising: (a) isolating a tissue sample from an individual who is receiving or is a candidate for receiving erythropoietin, (b) determining the level of expression of the NEPOR gene(s) (mRNA) and/or the presence of the NEPOR gene product (protein) from the isolated tissue, and (c) correlating the presence of an NEPOR gene expression product or the presence of NEPOR protein to a physiological response to the treatment with erythropoietin. Furthermore, by disclosing the molecular compositions of NEPOR species, there are disclosed methods for rationally identifying/designing NEPOR modulating therapeutics. Methods also are provided for treating neurological insults such as stroke (via enhancement of NEPOR activity) and cancer (via down-regulation of cyto-protective signaling from NEPOR).

20100172962, Jul 8, 2010

Feb 29, 2008

12/527684

William M. Merritt - Houston TX, US
Anil K. Sood - Pearland TX, US
Menashe Bar-Eli - Houston TX, US

THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM - Austin TX

A61K 9/127
A61K 31/7105
A61K 31/711
A61K 38/16
A61K 38/02
A61K 39/395
A61K 31/713
A61P 37/06

424450, 514 44 A, 514 44 R, 514 12, 514 2, 4241581

The present invention relates to the fields of molecular biology and drug delivery. In certain embodiments, the present invention provides compositions that include an siRNA targeted to an interleukin and a neutral lipid, and methods of treating a human subject with cancer involving administering to the subject a pharmaceutically effective amount of an interleukin-8 antagonist or a composition as set forth herein.

20110064664, Mar 17, 2011

Oct 8, 2008

12/680728

Eylem Ozturk - Ankara, TR
Angela Sanguino - Houston TX, US
Anil Sood - Pearland TX, US
Emir Baki Denkbas - Ankara, TR

THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM - AUSTIN TX

A61K 49/00
A61K 47/30
A61K 38/02
A61K 39/395
A61K 31/7052
C12Q 1/68
C40B 30/00
A61P 35/00

424 91, 514777, 514 11, 4241301, 514 44 R, 514 44 A, 435 6, 506 7

Disclosed are nanoparticles for the delivery of a therapeutic agent or a diagnostic agent to a subject that include a chitosan and a polyphosphate, wherein the weight ratio of the chitosan to the polyphosphate is about 1.0 or greater and the weight ratio of the polyphosphate to the therapeutic agent or diagnostic agent is about 15.0 or less. Also disclosed are nanoparticles that include a chitosan and an inhibitor of enhancer of Zeste homologue 2 (EZH2). Methods of delivering a therapeutic agent or a diagnostic agent to a subject for the treatment or prevention of a disease and methods of predicting prognosis of ovarian cancer in a subject that involve determining the expression and/or function of EZH2 in the subject are also disclosed.

20110312899, Dec 22, 2011

Nov 17, 2009

13/129349

Anil K. Sood - Pearland TX, US
Andras G. Lacko - Ft. Worth TX, US
Lingegowda S. Mangala - Webster TX, US
Walter J. McConathy - Midland TX, US
Laszlo Prokai - Mansfield TX, US
Maya P. Nair - Coppell TX, US

UNT HEALTH SCIENCE CENTER AT FORT WORTH - Fort Worth TX
BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM - Austin TX

A61K 38/17
A61P 35/04
A61P 35/00
C12N 5/071
C07K 14/775
B82Y 5/00

514 198, 435375, 530359, 514 193, 977788, 977906

Disclosed are high density lipoprotein-nucleic acid particles, wherein the particles include (a) an apolipoprotein; (b) a nucleic acid component comprising a therapeutic nucleic acid segment; and (c) a polypeptide comprising a positively charged region, wherein the positively-charged region of the polypeptide associates with the nucleic acid component. Also disclosed are pharmaceutical compositions that include a) an apolipoprotein; (b) a nucleic acid component comprising a therapeutic nucleic acid segment; and (c) a polypeptide comprising a positively charged region. Methods that concern the particles and pharmaceutical compositions of the present invention are also set forth, as well as kits.